

# Choline intake and risk of lethal prostate cancer: incidence and survival<sup>1–3</sup>

Erin L Richman, Stacey A Kenfield, Meir J Stampfer, Edward L Giovannucci, Steven H Zeisel, Walter C Willett, and June M Chan

## ABSTRACT

**Background:** Meat, milk, and eggs have been inconsistently associated with the risk of advanced prostate cancer. These foods are sources of choline—a nutrient that may affect prostate cancer progression through cell membrane function and one-carbon metabolism. No study has examined dietary choline and the risk of lethal prostate cancer.

**Objective:** Our objective was to examine whether dietary choline, choline-containing compounds, and betaine (a choline metabolite) increase the risk of lethal prostate cancer.

**Design:** We prospectively examined the intake of these nutrients and the risk of lethal prostate cancer among 47,896 men in the Health Professionals Follow-Up Study. In a case-only survival analysis, we examined the postdiagnostic intake of these nutrients and the risk of lethal prostate cancer among 4282 men with an initial diagnosis of nonmetastatic disease during follow-up. Diet was assessed with a validated questionnaire 6 times during 22 y of follow-up.

**Results:** In the incidence analysis, we observed 695 lethal prostate cancers during 879,627 person-years. Men in the highest quintile of choline intake had a 70% increased risk of lethal prostate cancer (HR: 1.70; 95% CI: 1.18, 2.45; *P*-trend = 0.005). In the case-only survival analysis, we observed 271 lethal cases during 33,679 person-years. Postdiagnostic choline intake was not statistically significantly associated with the risk of lethal prostate cancer (HR for quintile 5 compared with quintile 1: 1.69; 95% CI: 0.93, 3.09; *P*-trend = 0.20).

**Conclusion:** Of the 47,896 men in our study population, choline intake was associated with an increased risk of lethal prostate cancer. *Am J Clin Nutr* 2012;96:855–63.

## INTRODUCTION

Red meat and dairy products have been inconsistently associated with an increased risk of advanced prostate cancer (1–3). In addition, we recently reported that whole egg intake was positively associated with the risk of lethal prostate cancer (4), and the postdiagnostic intakes of whole eggs and poultry with skin were associated with increased risks of prostate cancer progression (5). Meat, milk, whole eggs, and poultry are all dietary sources of choline—an essential nutrient with many roles, including cell membrane structure and function, one-carbon metabolism, and neurotransmitter synthesis. Choline is highly concentrated in prostate cancer cells, and blood concentrations of choline have been associated with an increased risk of prostate cancer (6, 7). Thus, it is possible that the previously reported relations between meat, milk, and eggs and advanced prostate cancer were attributable in part to the choline content of these foods. However, no

study has examined dietary choline in relation to the risk of lethal prostate cancer or prostate cancer survival.

Therefore, we examined dietary choline in relation to the risk of lethal prostate cancer among men in the Health Professionals Follow-Up Study. Secondarily, we examined the intake of the 5 choline-containing compounds and betaine, a choline metabolite, in relation to the risk of lethal prostate cancer. We also examined the postdiagnostic intake of these nutrients in relation to the risk of lethal prostate cancer among men with an initial diagnosis of nonmetastatic disease. We focused on the risk of lethal prostate cancer in all analyses because prostate cancer has both indolent and lethal forms, and the outcome of lethal disease has clear clinical and public health relevance. On the basis of our recent findings for eggs and the observation that higher concentrations of plasma choline were associated with an increased risk of prostate cancer (4, 7), we hypothesized that higher dietary choline would be associated with an increased risk of lethal prostate cancer.

## SUBJECTS AND METHODS

### Study population

The Health Professionals Follow-Up Study is a prospective cohort study initiated in 1986 in the United States among 51,529 male health professionals aged 40–75 y. Participants completed a questionnaire at baseline on medical diagnoses, medication use, physical activity, body weight, family history, and smoking and a semiquantitative food-frequency questionnaire (FFQ). Medical diagnoses, medications, physical activity, body weight, and smoking data were updated every 2 y, and dietary data were updated every 4 y. The average response rate for the question-

<sup>1</sup> From the Departments of Epidemiology (ELR, SAK, MJS, ELG, and WCW) and Nutrition (ELR, MJS, ELG, and WCW), Harvard School of Public Health, Boston, MA; the Departments of Epidemiology and Biostatistics and Urology (ELR and JMC), University of California, San Francisco, CA; the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (SAK, MJS, and ELG); and the Department of Nutrition, University of North Carolina, Chapel Hill, NC (SHZ).

<sup>2</sup> Supported by grants from the NIH (CA141298, CA098566, CA112355, and CA55075) and the Prostate Cancer Foundation.

<sup>3</sup> Address correspondence to EL Richman, MC3110 UCSF, Helen Diller Cancer Research Building, 1450 3rd Street, San Francisco, CA 94158-9001. E-mail: richmane@urology.ucsf.edu.

Received April 2, 2012. Accepted for publication July 11, 2012.

First published online September 5, 2012; doi: 10.3945/ajcn.112.039784.

naires exceeded 90% (8). The Institutional Review Board of the Harvard School of Public Health approved this study.

### Dietary assessment

The FFQ asked participants to report their usual intake of ~140 foods and beverages over the past year. A common serving size was specified for each item (eg, one egg including yolk), and frequency options ranged from never or less than once per month to  $\geq 6/d$ . The FFQ also asked about multivitamin and supplement use. Nutrient composition values for each food were obtained from the USDA (9, 10). We multiplied a weight based on the nutrient composition of the specified portion size of each food by the frequency of its use and summed across foods to calculate total nutrient intakes. Total dietary choline was calculated by summing free choline and choline from glycerophosphocholine, phosphocholine, phosphatidylcholine, and sphingomyelin.

Nutrient-composition data for choline were not available when the FFQ was validated in 1986 (11). However, dietary choline measured by the FFQ was inversely associated with plasma homocysteine (12). Homocysteine is converted to methionine when it acquires a methyl group from a methyl donor, such as choline (via betaine) or folate; therefore, one would expect dietary choline to be inversely associated with homocysteine concentrations, particularly among persons with low dietary folate. Indeed, participants in the fifth quintile of dietary choline had a geometric mean total plasma homocysteine of 9.8 (95% CI: 9.5, 10.2) compared with 10.6 (95% CI: 10.2, 11.0) in the lowest quintile ( $P$ -trend  $< 0.0001$ ), independent of folate and vitamins B-6 and B-12. Furthermore, this association was strongest among men, persons with low dietary folate, and persons with high alcohol intake. An association between choline assessed via the FFQ and plasma homocysteine concentration, independent of other predictors, suggests that the FFQ can accurately rank individuals according to their choline intake.

### Outcome assessment and follow-up

Participants were asked every 2 y whether they received a diagnosis of prostate cancer. After report of a prostate cancer diagnosis, we requested the participants' permission to obtain medical records and pathology reports to confirm the diagnosis. Study investigators abstracted information on the date of diagnosis, clinical T-stage, Gleason score, prostate specific antigen, metastases, and treatments from the medical records. Prostate cancer-specific follow-up questionnaires were mailed biannually to collect additional information on treatment and disease progression. Mortality data were obtained via mail, telephone, and review of the National Death Index; we ascertain  $>98\%$  of deaths using these methods (13). An Endpoints Committee of 4 study physicians determined cause of death from death certificates and medical records. If prostate cancer metastasis was present and no more plausible cause of death was mentioned, the death was attributed to prostate cancer. Our primary outcome was lethal prostate cancer, defined as distant organ metastases from prostate cancer or prostate cancer death.

### Inclusion and exclusion criteria

We limited the analysis to participants who adequately completed the baseline FFQ (eg, 800–4200 kcal/d and missing  $<70$

food items) and who were free of cancer diagnosis (except non-melanoma skin cancer) in 1986, which left 47,896 men eligible for the incidence analysis. For the case-only survival analysis, in addition to the above criteria, participants must have had a diagnosis of nonmetastatic prostate cancer during follow-up and could not have missing data on their clinical stage at diagnosis or primary treatment, which left 4282 men with nonmetastatic prostate cancer eligible for follow-up for lethal outcomes.

### Statistical analysis

All statistical analyses were performed by using SAS version 9.2 (SAS Institute), and results with a 2-sided  $P$  value  $<0.05$  were considered statistically significant.

### Incidence of lethal prostate cancer

We used Cox proportional hazards regression to examine the associations between intake of choline, choline-containing compounds, and betaine and risk of lethal prostate cancer. Person-time was calculated from the time of return of the baseline questionnaire until diagnosis of prostate cancer, death from other cause, or end of follow-up (31 January 2008), whichever occurred first. We used calendar time in 2-y intervals as the time scale and stratified by age in months.

Cumulative average intakes of choline, choline-containing compounds, and betaine were calculated from all FFQs before diagnosis of prostate cancer to reduce measurement error in the long-term diet (eg, the 1986 FFQ was used for person-time accrued between 1986 and 1990; the average of the 1986 and 1990 FFQs was used for person-time accrued between 1990 and 1994, etc) (14). We categorized the nutrient intakes into quintiles and modeled them by using indicator variables. We modeled the median intake of each quintile as a continuous term to test for linear trend.

All nutrients were adjusted for energy by using the nutrient-residual method (14), and we addressed potential confounding by adjusting for factors that have been previously associated with lethal prostate cancer (2, 3, 15–19). Model 1 included age (mo; continuous), time period (2-y intervals), and energy (kcal/d; quintiles). Model 2 included the covariates in model 1 plus BMI (in  $\text{kg}/\text{m}^2$ ;  $<25$ , 25–29.9,  $\geq 30$ , or missing), smoking (never, former, current, or missing), and vigorous physical activity (metabolic equivalent task-hours/wk; quartiles). Model 3 included the covariates in model 2 plus quintiles of intakes of calcium, cholesterol, zinc, coffee, saturated fat, lycopene, phosphorus, and protein. These foods and nutrients were selected because they are risk factors for lethal prostate cancer or are present in foods that contain choline and were retained in the model because they changed the point estimate of one or more of the exposures of interest by  $\geq 10\%$ . We also considered adjustment for race, history of diabetes, prostate specific antigen screening, and intakes of folate, polyunsaturated fat, monounsaturated fat, and vitamins D and E; however, none of these changed the effect estimates by  $\geq 10\%$ ; therefore, they were omitted from the multivariate models. In addition, to examine whether the observed associations for choline were a marker of one or more choline-containing foods, we examined multivariate models with the following foods added one at a time: whole eggs, skim milk, beef or lamb as a main dish, chicken or turkey without skin, hamburger, other fish, chicken or turkey with skin, beef or lamb as a sandwich or mixed dish, beer, potatoes, and dark-meat

fish. We also examined models with total red meat, total milk, total poultry, and total fish. These foods were chosen because they were among the top 10 contributors to choline intake on at least one of the FFQs administered between 1986 and 2006.

Additionally, we examined whether age (continuous), calendar time (2-y intervals, continuous), smoking (current or not current), or BMI (<25 or ≥25) modified the relation between choline intake and the risk of lethal prostate cancer by including a cross-product term between the potential effect modifier and choline intake (modeling the median of each quintile as an ordinal score) in our multivariate model and using a likelihood ratio test to test for evidence of effect modification.

Last, we examined time lags ranging from 4–8 y to 16–20 y (eg, for a 16–20-y lag, we applied the 1986 FFQ to person-time accrued between 2002 and 2006 and the average of the 1986 and 1990 FFQ to person-time accrued between 2006 and the end of follow-up). We also repeated the analyses censoring men at the date of lethal prostate cancer (eg, date of diagnosis of distant organ metastases or death from prostate cancer), death from another cause, or end of follow-up. In this secondary analysis, we examined cumulative updated choline intake from baseline until the date of lethal event or censoring and applied a 2–6-y time lag because men with undiagnosed metastatic disease may change their diet as a result of their illness (eg, the 1986 FFQ was applied to person-time accrued between 1988 and 1992, etc).

**Case-only survival analysis**

We used Cox proportional hazards regression to examine the relations between postdiagnostic choline, choline-containing compounds, and betaine intake and risk of lethal prostate cancer. Person-time was calculated from the date of prostate cancer diagnosis to prostate cancer death or diagnosis of distant organ metastases, death from another cause, or end of follow-up (31 January 2008), whichever occurred first. We calculated cumulative average intake of choline, choline-containing compounds, and betaine from the FFQ preceding diagnosis up to the end of follow-up. The FFQ preceding diagnosis was used to classify the participants' exposure from the date of diagnosis until the next available FFQ because men with a diagnosis of prostate cancer did not change their diet more or less on average compared with men without a diagnosis of prostate cancer during the same time period.

We considered all of the confounders mentioned above (see Incidence of lethal prostate cancer) and age at diagnosis, Gleason score, prostate specific antigen at diagnosis, clinical T-stage, and primary treatment. Model 1 included age at diagnosis (y; continuous), energy (kcal/d; quintiles), time period (2-y intervals), and time since diagnosis (y; continuous). Model 2 included the covariates in model 1 plus primary treatment (radical prostatectomy, radiation therapy, hormonal therapy, or other/active surveillance), Gleason score (≤6, 7, or ≥8), clinical T-stage (T1, T2, or T3), BMI (<25, 25–29.9, ≥30, or missing), smoking (never, former, or current), and vigorous physical activity (metabolic equivalent task-hours/wk; quartiles). Model 3 included the covariates in model 2 plus quintile ranks of intakes of calcium, cholesterol, coffee, saturated fat, phosphorus, and polyunsaturated fat. Additionally, we examined models that adjusted for prediagnostic intake of the nutrient of interest based on the 1986 FFQ.

In addition, we examined whether the association between postdiagnostic choline intake and lethal prostate cancer was

**TABLE 1**  
Baseline age-standardized characteristics of 47,896 male health professionals, by choline intake

	Quintile of choline					P value <sup>1</sup>
	1	2	3	4	5	
Median choline intake (mg/d)	305	351	385	425	509	—
Age (y)	52.2 ± 9.9 <sup>2</sup>	53.4 ± 9.8	53.8 ± 9.7	54.7 ± 9.6	55.7 ± 9.4	<0.001
BMI (kg/m <sup>2</sup> )	25.2 ± 3.2	25.4 ± 3.2	25.5 ± 3.3	25.7 ± 3.5	25.8 ± 3.5	<0.001
Vigorous physical activity (MET-h <sup>3</sup> /wk)	12.6 ± 24.8	12.6 ± 22.9	12.6 ± 25.0	12.5 ± 26.4	13.4 ± 30.7	0.08
White (%)	90	91	91	91	91	0.008
Current smokers (%)	8	9	9	10	12	<0.001
Family history of prostate cancer (%)	13	12	13	13	13	0.89
Pearson correlation between intake of choline and other nutrients at baseline <sup>4</sup>						
Cholesterol	0.62	—	—	—	—	—
Saturated fat	0.04	—	—	—	—	—
Polyunsaturated fat	-0.04	—	—	—	—	—
Protein	0.53	—	—	—	—	—
Calcium	0.30	—	—	—	—	—
Phosphorus	0.43	—	—	—	—	—
Zinc	0.29	—	—	—	—	—
Lycopene	0.01	—	—	—	—	—

<sup>1</sup> Calculated from a logistic model that examined categorical choline as the dependent variable and the characteristic of interest as the independent variable, adjusted for age.

<sup>2</sup> Mean ± SD (all such values).

<sup>3</sup> MET-h, metabolic equivalent task-hours.

<sup>4</sup> All nutrients were adjusted for energy by using the nutrient-residual method, and all P values were <0.001 except for the correlation coefficient between lycopene and choline (P = 0.20).

modified by age at diagnosis (<69 or ≥69 y), Gleason grade (<7 or ≥7), BMI (<25 or ≥25), or smoking (current or not current) by creating a cross-product term between choline intake (ordinal score) and the potential effect modifier and used likelihood ratio tests to test for evidence of effect modification.

## RESULTS

### Incidence of lethal prostate cancer

At baseline, men in the fifth quintile of choline were older (56 compared with 52 y), had a higher BMI (25.8 compared with 25.2), and were more likely to be current smokers (12% compared with 8%) compared with men in the lowest quintile of choline intake (**Table 1**). After adjustment for energy, choline intake was correlated with intake of cholesterol ( $r = 0.62$ ), protein ( $r = 0.53$ ), phosphorus ( $r = 0.43$ ), calcium ( $r = 0.30$ ), and zinc ( $r = 0.29$ ).

The top 5 foods contributing to choline based on data from the 2006 FFQ were whole eggs, beef as a main dish, skim milk, reduced-fat milk, and poultry without skin; these foods accounted for 27% of choline intake (**Table 2**). Nearly 50% of choline was consumed in the form of phosphatidylcholine, followed by free choline (24%), glycerophosphocholine (17%), sphingomyelin (5%), and phosphocholine (4%). The fat-soluble choline-containing compounds (eg, phosphatidylcholine and sphingomyelin) came primarily from whole eggs, beef, poultry, and pork. In contrast, a wide variety of foods contributed to intake of the water-soluble choline-containing compounds (eg, free choline, glycerophosphocholine, and phosphocholine), including coffee, potatoes, skim milk, beer, reduced-fat milk, bananas, fish, broccoli, poultry, and soymilk. Cold cereal, pasta, cooked spinach, dark bread, and pizza accounted for 49% of betaine intake.

We observed 695 events of lethal prostate cancer during 879,627 person-years. In multivariate analyses, men in the highest quintile of choline intake had a 70% increased risk of lethal prostate cancer compared with men in the lowest quintile (HR: 1.70; 95% CI: 1.18, 2.45;  $P$ -trend = 0.005) (**Table 3**). This relation was not appreciably changed after adjustment for important food contributors to choline intake (eg, whole eggs, skim milk, beef or lamb as a main dish, and chicken or turkey without skin). In addition, intakes of free choline and glycerophosphocholine were positively associated with risk of lethal prostate cancer, but the relations between phosphatidylcholine, sphingomyelin, and phosphocholine intake and lethal prostate cancer were not statistically significant. Betaine intake was not associated with risk of lethal prostate cancer.

We observed no evidence of effect modification between age, calendar time, smoking, or BMI and choline intake in relation to the risk of lethal prostate cancer (data not shown). In addition, when we examined various time lags, the results became stronger. For example, when applying a 16–20-y lag (69 events), men in the fifth quintile of choline intake had a risk of lethal prostate cancer >3-fold that of men in the lowest quintile (HR: 3.28; 95% CI: 1.09, 9.84;  $P$ -trend = 0.05). Our results were also stronger when we followed men to the date of lethal event instead of initial date of diagnosis (HR for quintile 5 compared with quintile 1: 2.80; 95% CI: 1.55, 5.04;  $P$ -trend < 0.001).

**TABLE 2**

Food sources of choline, choline-containing compounds, and betaine in the Health Professionals Follow-Up Study, based on the food-frequency questionnaire administered in 2006

Food source	Proportion
<b>Choline</b>	
Whole eggs	10.4
Beef or lamb as a main dish	5.9
Skim milk	4.2
Reduced-fat milk	3.6
Poultry without skin	3.3
<b>Phosphatidylcholine (49% of choline)</b>	
Whole eggs	19.8
Beef or lamb as a main dish	9.6
Poultry without skin	4.5
Beef, pork, or lamb as a sandwich or mixed dish	4.4
Pork, main dish	4.1
<b>Sphingomyelin (5% of choline)</b>	
Beef or lamb as a main dish	12.4
Poultry without skin	12.1
Whole eggs	8.7
Poultry, sandwich, or frozen dinner	7.5
Beef, pork, or lamb as a sandwich or mixed dish	5.1
<b>Free choline (24% of choline)</b>	
Coffee	5.7
Potatoes	3.9
Skim milk	3.2
Beer	3.2
Reduced-fat milk	3.1
<b>Glycerophosphocholine (17% of choline)</b>	
Skim milk	15.6
Reduced-fat milk	12.5
Bananas	4.3
Dark fish	4.2
Other fish	3.8
<b>Phosphocholine (4% of choline)</b>	
Skim milk	10.6
Broccoli	9.7
Reduced-fat milk	8.5
Poultry without skin	3.6
Soymilk	2.9
<b>Betaine</b>	
Cold cereal	19.6
Pasta	12.3
Cooked spinach	6.4
Dark bread	5.3
Pizza	5.2

### Case-only survival analysis

Sociodemographic characteristics varied similarly across quintiles of postdiagnostic choline intake in comparison with men in the entire cohort (**Table 4**). Additionally, the distribution of clinical factors was similar across quintiles of postdiagnostic choline intake; however, men who consumed the most choline after diagnosis were somewhat less likely to have a Gleason sum of 7 compared with men who consumed the least amount of choline.

We observed 271 lethal events during 33,679 person-years. Postdiagnostic choline intake was not statistically significantly associated with risk of lethal prostate cancer (HR: 1.69; 95% CI: 0.93, 3.09;  $P$ -trend = 0.20) (**Table 5**), and this relation was unchanged when we included red meat, milk, poultry, whole eggs, or fish in the multivariate model. However, the association became stronger after adjustment for prediagnostic intake of

**TABLE 3**

Relative hazard of lethal prostate cancer among 47,896 male health professionals by intake of choline, choline-containing compounds, and betaine

	Quintile of intake					P-trend <sup>1</sup>
	1	2	3	4	5	
<b>Choline</b>						
Events	105	123	140	155	172	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.12 (0.86, 1.46)	1.16 (0.90, 1.50)	1.24 (0.96, 1.59)	1.36 (1.06, 1.74)	0.009
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.12 (0.86, 1.46)	1.17 (0.90, 1.51)	1.25 (0.97, 1.60)	1.38 (1.08, 1.77)	0.006
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.24 (0.93, 1.65)	1.38 (1.01, 1.87)	1.55 (1.11, 2.16)	1.70 (1.18, 2.45)	0.005
<b>Fat-soluble choline-containing compounds</b>						
<b>Phosphatidylcholine</b>						
Events	118	135	134	140	168	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.17 (0.91, 1.50)	1.12 (0.87, 1.44)	1.15 (0.89, 1.47)	1.33 (1.05, 1.69)	0.03
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.17 (0.91, 1.50)	1.12 (0.87, 1.44)	1.14 (0.89, 1.47)	1.34 (1.05, 1.70)	0.03
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.28 (0.97, 1.70)	1.32 (0.95, 1.82)	1.37 (0.96, 1.96)	1.46 (1.00, 2.13)	0.10
<b>Sphingomyelin</b>						
Events	133	148	158	119	137	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.16 (0.91, 1.47)	1.25 (0.99, 1.58)	0.95 (0.74, 1.22)	1.19 (0.93, 1.52)	0.53
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.15 (0.90, 1.46)	1.24 (0.98, 1.57)	0.95 (0.73, 1.22)	1.20 (0.93, 1.53)	0.53
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.23 (0.93, 1.62)	1.35 (0.98, 1.87)	1.03 (0.71, 1.51)	1.28 (0.82, 2.00)	0.57
<b>Water-soluble choline-containing compounds</b>						
<b>Free choline</b>						
Events	120	122	161	136	156	
Model 1, HR (95% CI) <sup>2</sup>	1.0	0.81 (0.63, 1.05)	1.06 (0.83, 1.35)	0.87 (0.68, 1.12)	1.08 (0.85, 1.37)	0.32
Model 2, HR (95% CI) <sup>3</sup>	1.0	0.82 (0.64, 1.06)	1.08 (0.85, 1.38)	0.89 (0.69, 1.15)	1.13 (0.88, 1.44)	0.17
Model 3, HR (95% CI) <sup>4</sup>	1.0	0.91 (0.70, 1.19)	1.29 (0.99, 1.69)	1.14 (0.85, 1.53)	1.49 (1.10, 2.01)	0.003
<b>Glycerophosphocholine</b>						
Events	96	124	164	141	170	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.14 (0.87, 1.49)	1.42 (1.10, 1.84)	1.18 (0.91, 1.54)	1.37 (1.06, 1.77)	0.03
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.13 (0.86, 1.49)	1.43 (1.10, 1.84)	1.18 (0.91, 1.54)	1.38 (1.07, 1.78)	0.03
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.20 (0.90, 1.58)	1.55 (1.16, 2.06)	1.32 (0.96, 1.80)	1.59 (1.12, 2.25)	0.02
<b>Phosphocholine</b>						
Events	95	128	168	146	158	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.22 (0.93, 1.60)	1.44 (1.11, 1.86)	1.22 (0.94, 1.59)	1.20 (0.93, 1.55)	0.39
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.23 (0.94, 1.61)	1.45 (1.12, 1.88)	1.25 (0.96, 1.62)	1.23 (0.95, 1.60)	0.28
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.31 (0.98, 1.75)	1.60 (1.18, 2.16)	1.38 (0.99, 1.93)	1.34 (0.92, 1.96)	0.26
<b>Betaine</b>						
Events	131	134	135	157	138	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.02 (0.80, 1.31)	1.02 (0.80, 1.31)	1.16 (0.91, 1.46)	0.99 (0.78, 1.27)	0.85
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.02 (0.80, 1.31)	1.03 (0.80, 1.31)	1.17 (0.92, 1.48)	1.01 (0.79, 1.29)	0.73
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.07 (0.83, 1.37)	1.08 (0.84, 1.39)	1.22 (0.95, 1.57)	1.02 (0.78, 1.33)	0.78

<sup>1</sup> Calculated by modeling the median of each quintile as a continuous term.

<sup>2</sup> Cox proportional hazards regression model adjusted for age (mo, continuous), time period (2-y intervals), and energy (kcal/d, quintiles).

<sup>3</sup> Cox proportional hazards regression model adjusted for the variables in model 1 plus BMI (in kg/m<sup>2</sup>; <25, 25–29.9, ≥30, or missing), smoking (never, former, current, or missing), and vigorous activity (metabolic equivalent task-hours/wk; quartiles).

<sup>4</sup> Cox proportional hazards regression model adjusted for the variables in model 2 plus quintile intakes of calcium, cholesterol, zinc, coffee, saturated fat, lycopene, phosphorus, and protein.

choline. Men in the fifth quintile of postdiagnostic choline had a risk of lethal prostate cancer nearly 2-fold that of men in the lowest quintile (HR: 1.98; 95% CI: 1.06, 3.70; *P*-trend = 0.08). Postdiagnostic intakes of the choline-containing compounds were not associated with risk of progression to lethal prostate cancer. Smoking, BMI, Gleason score, and age at diagnosis did not modify the association between postdiagnostic choline intake and risk of lethal prostate cancer (data not shown).

**DISCUSSION**

In this novel prospective analysis, we observed a positive association between intake of choline and risk of lethal prostate

cancer. We attempted to account for the association between choline intake and risk of lethal prostate cancer by adjusting for nutrients found in animal products that may also affect risk of prostate cancer, such as cholesterol, fatty acids, protein, zinc, phosphorus, and vitamin D. Furthermore, we examined the association between choline intake and the risk of lethal prostate cancer adjusting for the top food contributors to choline (eg, whole eggs, beef or lamb as a main dish, skim milk, and chicken or turkey without skin), because several of these foods have been positively associated with the risk of prostate cancer in our study population (4, 20). The positive relation between choline intake and risk of lethal prostate cancer remained in all of these models. Yet, we cannot exclude the possibility that unmeasured factors in



TABLE 4

Age-standardized characteristics of 4282 male health professionals with a diagnosis of nonmetastatic prostate cancer, by choline intake<sup>1</sup>

Characteristic	Quintile of choline					P value <sup>2</sup>
	1	2	3	4	5	
Median choline intake at diagnosis (mg/d)	297	341	371	405	471	
Age at diagnosis (y)	69.0 ± 7.3 <sup>3</sup>	68.9 ± 7.2	69.1 ± 7.2	69.1 ± 6.8	69.7 ± 7.0	0.03
BMI at diagnosis (kg/m <sup>2</sup> )	25.4 ± 3.0	25.5 ± 3.3	25.9 ± 3.6	26.1 ± 3.4	26.2 ± 3.4	<0.001
Vigorous physical activity at diagnosis (MET-h/wk)	12.3 ± 22.4	13.5 ± 25.1	12.0 ± 21.9	13.2 ± 24.0	12.0 ± 20.4	0.78
White (%)	91	94	94	92	94	0.08
Current smoker at diagnosis (%)	4	2	5	6	5	0.005
Family history of prostate cancer (%)	20	20	23	23	21	0.27
Clinical T-stage (%)						0.75
T1	59	58	57	59	59	
T2	38	38	39	36	38	
T3a	3	4	4	5	3	
Gleason sum (%)						0.05
2–6	52	50	52	52	53	
7	34	36	32	30	30	
8–10	9	9	9	11	11	
Missing	6	5	6	6	6	
PSA (%)						0.22
<4 ng/mL	12	12	12	10	9	
4–9.9 ng/mL	56	55	55	57	57	
10–19.9 ng/mL	17	16	17	18	19	
≥20 ng/mL	8	8	10	8	8	
Missing	6	8	6	7	6	
Treatment (%)						0.30
Radical prostatectomy	49	50	48	49	44	
Radiation therapy	37	37	38	36	41	
Hormonal therapy	4	4	5	6	4	
Other/active surveillance	10	9	9	10	10	

<sup>1</sup> MET-h, metabolic equivalent task-hours; PSA, prostate specific antigen.<sup>2</sup> Calculated from a logistic model that examined categorical choline as the dependent variable and the characteristic of interest as the independent variable, adjusted for age at diagnosis.<sup>3</sup> Mean ± SD (all such values).

animal foods or persons who consume animal foods accounted for the association we observed between choline intake and risk of lethal prostate cancer.

No previous studies have examined dietary choline in relation to the risk of prostate cancer. A nested case-control study among Swedish men reported that a doubling in plasma choline was associated with a 46% increased risk of prostate cancer (OR: 1.46; 95% CI: 1.04, 2.05; *P*-trend = 0.03) (7). Nearly 77% of the cases were detected because of clinical symptoms, which supports the hypothesis that a high choline intake may increase the risk of advanced or aggressive prostate cancer or prostate cancer progression. Plasma choline is a relatively sensitive marker of supplemental choline intake, but less is known regarding its use as a biomarker of long-term dietary intake (21).

Biologic mechanisms linking higher choline intake to an increased risk of lethal prostate cancer are unknown. Additionally, it is not known whether dietary choline is correlated with, or affects, choline concentrations in the prostate. However, choline metabolism is clearly altered in prostate cancer, with greater concentrations of choline-containing compounds in malignant than in normal cells (6). Because of the selective and high uptake of circulating choline by prostate cancer cells, radiolabeled choline is used to identify prostate cancer recurrence and metastases (22, 23), and patients with high-grade prostate cancers

have higher concentrations of choline-containing compounds than do those with low-grade prostate cancers (24).

One potential mechanism mediating a relation between choline and lethal prostate cancer may involve choline's role in cell membrane structure and function. Choline is converted to phosphatidylcholine—a phospholipid necessary for cell membranes—and choline kinase, the enzyme that catalyzes the first and rate-limiting step in this conversion, is overexpressed in many human cancers, including prostate cancer (25). In addition, the release of choline metabolites and the turnover of phosphatidylcholine differ between prostate cancer cells and normal cells (26), and treatment of prostate cancer cell lines with chemotherapeutic agents decreases the concentration of choline and choline-containing compounds (27, 28). Furthermore, the alternative pathway for synthesis of phosphatidylcholine catalyzed by phosphatidylethanolamine-*N*-methyltransferase may also affect carcinogenesis (29, 30).

Another potential mechanism may involve choline's role as a source of methyl groups for DNA methylation and synthesis. Choline is irreversibly converted to betaine in the liver, which donates a methyl group to homocysteine to form methionine (31). Methionine is a precursor to *S*-adenosylmethionine—an important methyl donor for DNA methylation and synthesis. A secondary analysis of a randomized trial reported a positive

**TABLE 5**

Relative hazard of lethal prostate cancer among 4282 men with an initial diagnosis of nonmetastatic prostate cancer by postdiagnostic intake of choline, choline-containing compounds, and betaine

	Quintile of intake					<i>P</i> -trend <sup>1</sup>
	1	2	3	4	5	
<b>Choline</b>						
Events ( <i>n</i> )	36	63	52	59	61	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.58 (1.04, 2.38)	1.30 (0.85, 1.99)	1.51 (1.00, 2.29)	1.68 (1.11, 2.54)	0.04
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.61 (1.06, 2.44)	1.26 (0.82, 1.94)	1.33 (0.87, 2.03)	1.55 (1.02, 2.36)	0.16
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.64 (1.06, 2.54)	1.30 (0.80, 2.13)	1.40 (0.82, 2.41)	1.69 (0.93, 3.09)	0.20
<b>Fat-soluble choline-containing compounds</b>						
<b>Phosphatidylcholine</b>						
Events ( <i>n</i> )	43	52	61	50	65	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.15 (0.76, 1.72)	1.27 (0.86, 1.88)	1.10 (0.73, 1.65)	1.59 (1.07, 2.34)	0.03
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.11 (0.74, 1.68)	1.27 (0.85, 1.89)	1.01 (0.67, 1.53)	1.39 (0.94, 2.07)	0.16
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.12 (0.74, 1.71)	1.31 (0.84, 2.06)	1.07 (0.62, 1.83)	1.54 (0.84, 2.81)	0.16
<b>Sphingomyelin</b>						
Events ( <i>n</i> )	43	49	50	76	53	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.00 (0.66, 1.51)	0.99 (0.66, 1.49)	1.59 (1.09, 2.32)	1.28 (0.86, 1.93)	0.05
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.02 (0.68, 1.55)	1.01 (0.67, 1.52)	1.57 (1.07, 2.30)	1.23 (0.81, 1.85)	0.10
Model 3, HR (95% CI) <sup>4</sup>	1.0	0.98 (0.64, 1.51)	0.96 (0.60, 1.52)	1.48 (0.93, 2.37)	1.13 (0.64, 1.98)	0.46
<b>Water-soluble choline-containing compounds</b>						
<b>Free choline</b>						
Events ( <i>n</i> )	47	54	65	58	47	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.07 (0.72, 1.59)	1.29 (0.88, 1.88)	1.11 (0.75, 1.63)	0.98 (0.65, 1.46)	0.87
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.08 (0.73, 1.61)	1.21 (0.82, 1.77)	1.09 (0.73, 1.61)	0.96 (0.64, 1.45)	0.78
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.16 (0.77, 1.75)	1.35 (0.86, 2.07)	1.26 (0.79, 2.00)	1.20 (0.72, 1.99)	0.58
<b>Glycerophosphocholine</b>						
Events ( <i>n</i> )	38	59	54	66	54	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.33 (0.88, 2.01)	1.17 (0.77, 1.77)	1.51 (1.01, 2.25)	1.18 (0.78, 1.80)	0.54
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.38 (0.91, 2.09)	1.29 (0.85, 1.96)	1.59 (1.06, 2.37)	1.27 (0.83, 1.93)	0.38
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.36 (0.89, 2.06)	1.23 (0.79, 1.92)	1.46 (0.91, 2.33)	1.14 (0.65, 2.01)	0.87
<b>Phosphocholine</b>						
Events ( <i>n</i> )	39	57	62	60	53	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.32 (0.88, 1.99)	1.45 (0.97, 2.17)	1.34 (0.89, 2.02)	1.22 (0.81, 1.85)	0.52
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.35 (0.89, 2.04)	1.39 (0.92, 2.08)	1.34 (0.88, 2.01)	1.24 (0.81, 1.90)	0.50
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.38 (0.90, 2.11)	1.40 (0.90, 2.18)	1.34 (0.81, 2.20)	1.27 (0.71, 2.28)	0.60
<b>Betaine</b>						
Events ( <i>n</i> )	43	63	53	60	52	
Model 1, HR (95% CI) <sup>2</sup>	1.0	1.23 (0.83, 1.81)	1.04 (0.69, 1.56)	1.09 (0.73, 1.62)	1.09 (0.72, 1.63)	0.98
Model 2, HR (95% CI) <sup>3</sup>	1.0	1.15 (0.77, 1.70)	1.03 (0.68, 1.55)	1.07 (0.71, 1.59)	1.09 (0.72, 1.64)	0.86
Model 3, HR (95% CI) <sup>4</sup>	1.0	1.16 (0.78, 1.73)	1.07 (0.70, 1.62)	1.12 (0.74, 1.69)	1.08 (0.70, 1.67)	0.92

<sup>1</sup> Calculated by modeling the median of each quintile as a continuous term.

<sup>2</sup> Cox proportional hazards regression model adjusted for age at diagnosis (y, continuous), energy (kcal/d, quintiles), time period (2-y intervals), and time since diagnosis (y, continuous).

<sup>3</sup> Cox proportional hazards regression model adjusted for the variables in model 1 plus treatment (radical prostatectomy, radiation therapy, hormonal therapy, or other/active surveillance), Gleason sum ( $\leq 6$ , 7,  $\geq 8$ , or missing), clinical T-stage (T1, T2, or T3), BMI (in kg/m<sup>2</sup>;  $< 25$ , 25–29.9,  $\geq 30$ , or missing), smoking (never, former, or current), and vigorous activity (metabolic equivalent task-hours/wk; quartile rank).

<sup>4</sup> Cox proportional hazards regression model adjusted for the variables in model 2 plus quintile ranks of intakes of calcium, coffee, phosphorus, saturated fat, cholesterol, and polyunsaturated fat.

association between folate supplementation and prostate cancer risk, which supports a potential adverse effect of methyl donors on prostate cancer progression (32). However, the lack of association between betaine intake and risk of lethal prostate cancer does not support this potential mechanism.

Last, dietary choline is converted by gut bacteria to trimethylamine, which is converted to trimethylamine oxide in the liver. Mice treated with choline or trimethylamine oxide have increased activation of macrophages and atherosclerotic lesions (33). Although purely speculative, increased trimethylamine oxide

from high dietary choline may increase inflammation, and this may promote progression of prostate cancer to lethal disease.

Choline is an essential nutrient; therefore, it must be consumed in the diet for optimal health. Low concentrations of choline are associated with the development of fatty liver and liver damage (34, 35). In addition, animal data suggest that choline intake may be beneficial to cognitive function and memory (36–39), and cytidinediphosphocholine—the intermediate produced in the conversion of choline to phosphatidylcholine—has been associated with improved memory in elderly persons in short-term randomized



controlled trials (40). Thus, future studies need to examine whether the benefits of choline intake outweigh the potential risks among men.

The limitations of our study included the lack of validation of our FFQ's estimate of choline intake, our limited statistical power to examine the independent effects of the choline-containing compounds, restricted generalizability, and the potential for unmeasured confounding. Our study population was a homogeneous group of well-educated white men; thus, our results may not be generalizable to populations with different racial or socioeconomic distributions. Additionally, we attempted to thoroughly control for nutrients and foods and lifestyle, clinical, and socio-demographic factors, which have been shown to be associated with lethal prostate cancer and with nutrients present in animal products that could potentially be associated with prostate cancer. Yet, this was not a randomized controlled trial; therefore, we cannot be certain that the associations we observed were the results of intake of choline or some other nutrients or factors associated with the consumption of choline. The strengths of our study include the large number of events of lethal prostate cancer, our detailed and repeated assessments of diet and covariate data, and the completeness and length of our follow-up.

In conclusion, dietary choline may increase the risk of lethal prostate cancer. Future studies replicating these novel findings in large independent populations and studies examining the relation of dietary choline to choline concentrations in the prostate and the effects of dietary choline on normal and malignant prostate cells would be of interest.

We thank the participants and staff of the Health Professionals Follow-Up Study and the following state cancer registries for their invaluable contributions to this project: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Nebraska, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, Washington, and Wyoming. We also thank the Prostate Cancer Foundation for their contribution to the original efforts to collect data from men with prostate cancer in the Health Professionals Follow-Up Study.

The authors' responsibilities were as follows—MJS and WCW: designed the study; ELR and JMC: developed the analysis plan; ELR, SAK, MJS, ELG, WCW, and JMC: contributed to the collection and analysis of the data; ELR: drafted the manuscript; and MJS, ELG, WCW, SHZ, and JMC: provided significant consultation. All authors contributed to the substantial revision of the manuscript. None of the authors had any personal or financial conflicts of interest.

## REFERENCES

1. AICR/WCRF. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. In: AICR, ed. 2nd ed. Washington, DC: American Institute for Cancer Research/World Cancer Research Fund, 2007.
2. Chan JM, Gann PH, Giovannucci EL. Role of diet in prostate cancer development and progression. *J Clin Oncol* 2005;23:8152–60.
3. Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA. Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. *BJU Int* 2004;93:1139–50.
4. Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. *Cancer Prev Res (Phila)* 2011;4:2110–1.
5. Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. *Am J Clin Nutr* 2010;91:712–21.
6. Ackerstaff E, Pflug BR, Nelson JB, Bhujwala ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. *Cancer Res* 2001;61:3599–603.
7. Johansson M, Van Guelpen B, Vollset SE, Hultdin J, Bergh A, Key T, Middtun O, Hallmans G, Ueland PM, Stattin P. One-carbon metabolism and prostate cancer risk: prospective investigation of seven circulating B vitamins and metabolites. *Cancer Epidemiol Biomarkers Prev* 2009;18:1538–43.
8. Rimm EB, Stampfer MJ, Colditz GA, Giovannucci E, Willett WC. Effectiveness of various mailing strategies among nonrespondents in a prospective cohort study. *Am J Epidemiol* 1990;131:1068–71.
9. USDA, Agricultural Research Service. USDA database for the choline content of common foods. Release 2. Beltsville, MD: USDA, 2008.
10. USDA, Agricultural Research Service. USDA nutrient database for standard reference. Release 13. Washington, DC: USDA, 1999.
11. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. *Am J Epidemiol* 1992;135:1114–36.
12. Cho E, Zeisel SH, Jacques P, Selhub J, Dougherty L, Colditz GA, Willett WC. Dietary choline and betaine assessed by food-frequency questionnaire in relation to plasma total homocysteine concentration in the Framingham Offspring Study. *Am J Clin Nutr* 2006;83:905–11.
13. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, Hennekens CH. Test of the National Death Index. *Am J Epidemiol* 1984;119:837–9.
14. Willett WC. Nutritional epidemiology. 2nd ed. New York, NY: Oxford University Press, 1998.
15. Astorg P. Dietary N-6 and N-3 polyunsaturated fatty acids and prostate cancer risk: a review of epidemiological and experimental evidence. *Cancer Causes Control* 2004;15:367–86.
16. Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. *Cancer Prev Res (Phila)* 2011;4:486–501.
17. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. *Int J Cancer* 2007;121:1571–8.
18. Wilson KM, Kasperzyk JL, Rider JR, Kenfield SA, van Dam RM, Stampfer MJ, Giovannucci E, Mucci LA. Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. *J Natl Cancer Inst* 2011;103:876–84.
19. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. *Epidemiol Rev* 2001;23:87–92.
20. Michaud DS, Augustsson K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E. A prospective study on intake of animal products and risk of prostate cancer. *Cancer Causes Control* 2001;12:557–67.
21. Veenema K, Solis C, Li R, Wang W, Maletz CV, Abratte CM, Caudill MA. Adequate intake levels of choline are sufficient for preventing elevations in serum markers of liver dysfunction in Mexican American men but are not optimal for minimizing plasma total homocysteine increases after a methionine load. *Am J Clin Nutr* 2008;88:685–92.
22. Apolo AB, Pandit-Taskar N, Morris MJ. Novel tracers and their development for the imaging of metastatic prostate cancer. *J Nucl Med* 2008;49:2031–41.
23. Krause BJ, Souvatzoglou M, Tuncel M, Herrmann K, Buck AK, Praus C, Schuster T, Geinitz H, Treiber U, Schwaiger M. The detection rate of [<sup>11</sup>C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. *Eur J Nucl Med Mol Imaging* 2008;35:18–23.
24. Keshari KR, Tsachres H, Iman R, Delos Santos L, Tabatabai ZL, Shinohara K, Vigneron DB, Kurhanewicz J. Correlation of phospholipid metabolites with prostate cancer pathologic grade, proliferative status and surgical stage—impact of tissue environment. *NMR Biomed* 2011;24:691–9.
25. Ramirez de Molina A, Rodriguez-Gonzalez A, Gutierrez R, Martinez-Pineiro L, Sanchez J, Bonilla F, Rosell R, Lacal J. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. *Biochem Biophys Res Commun* 2002;296:580–3.
26. Rumsby M, Schmitt J, Sharrard M, Rodrigues G, Stower M, Maitland N. Human prostate cell lines from normal and tumorigenic epithelia differ in the pattern and control of choline lipid headgroups released into the medium on stimulation of protein kinase C. *Br J Cancer* 2011;104:673–84.



27. Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramirez de Molina A, Lecal JC, Workman P, Leach MO. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. *Cancer Res* 2010;70:5507-17.
28. Raina K, Serkova NJ, Agarwal R. Silibinin feeding alters the metabolic profile in TRAMP prostatic tumors: 1H-NMRS-based metabolomics study. *Cancer Res* 2009;69:3731-5.
29. Tessitore L, Marengo B, Vance DE, Papotti M, Mussa A, Daidone MG, Costa A. Expression of phosphatidylethanolamine N-methyltransferase in human hepatocellular carcinomas. *Oncology* 2003;65:152-8.
30. Tessitore L, Dianzani I, Cui Z, Vance DE. Diminished expression of phosphatidylethanolamine N-methyltransferase 2 during hepatocarcinogenesis. *Biochem J* 1999;337:23-7.
31. Zeisel SH, Blusztajn JK. Choline and human nutrition. *Annu Rev Nutr* 1994;14:269-96.
32. Figueiredo JC, Grau MV, Haile RW, Sandler RS, Summers RW, Bresalier RS, Burke CA, McKeown-Eyseen GE, Baron JA. Folic acid and risk of prostate cancer: results from a randomized clinical trial. *J Natl Cancer Inst* 2009;101:432-5.
33. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* 2011; 472:57-63.
34. Institute of Medicine, National Academy of Sciences. Dietary reference intakes for folate, thiamine, riboflavin, niacin, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy of Sciences, 1998:390-422.
35. Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. *Nutr Rev* 2009;67:615-23.
36. Eussen SJ, Ueland PM, Clarke R, Blom HJ, Hoefnagels H, van Staveren WA, de Groot LC. The association of betaine, homocysteine and related metabolites with cognitive function in Dutch elderly people. *Br J Nutr* 2007;98:960-8.
37. Sanchez CJ, Hooper E, Garry PJ, Goodwin JM, Goodwin JS. The relationship between dietary intake of choline, choline serum levels, and cognitive function in healthy elderly persons. *J Am Geriatr Soc* 1984; 32:208-12.
38. Deuster PA, Singh A, Coll R, Hyde DE, Becker WJ. Choline ingestion does not modify physical or cognitive performance. *Mil Med* 2002; 167:1020-5.
39. Buchman AL, Sohel M, Brown M, Jenden DJ, Ahn C, Roch M, Brawley TL. Verbal and visual memory improve after choline supplementation in long-term total parenteral nutrition: a pilot study. *JPEN J Parenter Enteral Nutr* 2001;25:30-5.
40. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. *Cochrane Database Syst Rev* 2004;CD000269.

